|
|
|
|
|
Market Research Report
Industry Analysis: Where Is the Innovation in Neurology Markets?
|
This publication has been discontinued on December 21, 2011.
Abstract
Introduction
The four major neurological diseases currently have no cures. Many
pharmaceuticals are available and are in development, but these drugs
typically address just the symptoms. Vast unmet need exists for medicines that
treat the early stages of neurological diseases. And, in turn, a huge
opportunity exists for companies that focus on innovation
Get the Answers You Need to Shape Your Strategy
There are more than a dozen major neurology franchises, and many companies
have had blockbuster success in this market. Yet the unmet need and resulting
opportunity in this market are staggering. What business strategies can
companies utilize to tap this wide-open market? Most medicines on the
market offer only symptomatic relief, and few new innovative drugs are in
development. What approaches can companies use to create drugs with
disease-modifying effects and to treat early-stage disease? Companies are
using many life-cycle management strategies to extend the market for existing
drugs. While these drugs are useful, they do little to build value for the
future. Why are so few products available for neurological diseases? What
explains the lack of innovation in this market? What strategies are companies
using to develop future neurology drug markets and franchises?
Scope
- Overview of drugs and market for the four major neurology diseases:
Alzheimer' s disease,Parkinson' s disease, epilepsy, and multiple sclerosis
- Key neurology deals: overview of ten neurology deals valued at more
than $100 million that have closed within the last two years
- Business strategies that companies are using to develop future
neurology drug markets and franchises: in-licensing, mergers and
acquisitions, fully integrated companies, challenging drug patents, extending
reach from generics to brands
- Decision points critical to innovation in the neurology market:
resource allocation and prioritization, how to treat early-stage disease,
creating personalized medicine, stem cell research
- Spectrum Expert Commentary: the view from a world-known
pharmaceutical industry consultant
- Outlook: challenges that the neurology market will face without
innovation
Mentioned in This Report-Companies
- Abbott Laboratories
- Acorda
- Albany Molecular Research
- Advanced
- Neurolomodulation
- Systems
- Alnylam
- Amarin
- Astellas
- AstraZeneca
- Athenagen
- Axaron Bioscience
- Axonyx
- Bayer AG
- BioArctic Neuroscience
- Bioceuticals Arzneimittel
- Biogen Idec
- BioMS
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Carlsson Research
- Celera Genomics
- CeNeS
- Chugai
- Cita NeuroPharmaceuticals
- CoCensys
- Dainippon
- DNAVEC
- Durect
- Eisai
- Elan
- Esteve
- Forest Labs
- Fumapharm
- GeneMedix
- Genzyme
- GlaxoSmithKline
- Ilex Oncology
- Image-Guided Neurologics
- Ivax
- Janssen
- Johnson & Johnson
- Kyowa Hakko Kogyo
- LION bioscience
- Lundbeck
- Medtronic
- Merck KGaA
- Millennium
- Pharmaceuticals
- MultiCell Technologies
- Mutual Pharmaceutical
- Mylan
- Myriad Genetics
- Neurochem
- Neurocrine
- NeuroSearch
- NeuroSolutions
- Newron Pharmaceuticals
- Nitto Denko
- Novartis
- Novasite
- NovImmune
- Orion
- Ortho-McNeil
- Osprey Pharmaceutical
- Ovation
- PDL BioPharma
- Pfi zer
- Prolong Pharma
- PsyCheNomics
- Purdue Pharma
- ReNeuron
- Rinat Neuroscience
- Roche
- Sanofi -Aventis
- Schering AG
- Schwarz Pharma
- Serono
- Shire
- Sigma-Tau
- Solvay
- St. Jude Medical
- Stem Cell Sciences
- Stem Cell Therapeutics
- StemCells
- Targacept
- Teva
- TorreyPines Therapeutics
- Transition Therapeutics
- TransTech Pharma
- UCB
- United Research
- Laboratories
- Valeant
- Vernalis
- Voyager
- Watson Laboratories
- XenoPort
- Zapaq
- Zenyaku Kogyo
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Neurological Diseases Have No Cures
- Worldwide Neurology Markets
- Major Neurology Franchises
- Business Strategies-2006
- Ten Largest Neurology Deals, 2005-2006
- Mergers & Acquisitions (M&As)
- Protecting a Market-Leading Multiple Sclerosis Franchise
- Risk Management of ƒ¿4-Integrin Inhibitors
- BG-12
- Extending Reach from Generics to Branded Pharmaceuticals
- Sanofi-Aventis/Teva' s Copaxone
- Teva/Lundbeck' s Azilect (rasagiline)
- Filling a Neurology Pipeline Through Acquisitions and Inlicensing
- Fully Integrated Companies
- Challenges from Generics and Biogenerics/Biosimilars Encroachment
- Sidebar: Demise of the Instant Fully Integrated Pharmaceutical Company
(FIPCO) Strategy
- Life-Cycle Management
- Fixed Combinations in Parkinson' s Disease
- Expanding Disease Indications
- Rituxan/MabThera
- Zenapax (daclizumab)
- Campath/MabCampath (alemtuzumab)
- Reformulations
- Serono' s Rebif
- Eisai/Pfizer' s Aricept
- Where Is the Innovation?
- Resource Allocation and Prioritization
- Disease-Causing Genes and Biomarkers
- Parkinson' s Disease
- Alzheimer' s Disease
- Epilepsy
- Using Pharmacogenomics to Create Personalized Medicines
- What' s Going on With Stem Cells?
- Outlook
Figures
- 1. Worldwide Markets for Four Major Neurology Diseases, 2004/2005
- 2. Prevalence of Four Major Neurology Diseases, 2004/2005
- 3. Major Worldwide Neurology Franchises, 2005
- 4. Largest Neurology Deals, 2005-2006
Tables
- 1. Top Ten Neurology Brands
- 2. Select Neurology-Based Mergers and Acquisitions, 2005-2006
- 3. Strengthening Eisai' s Neurology Franchise Through Product Acquisitions
and Licensing
- 4. Life-Cycle Management of Select Neurology Drugs
- 5. Extending Disease Indications for Existing Monoclonal Antibodies
- 6. Genes Associated with Parkinson' s Disease
- 7. Neurology Drugs in Phase III Development or Later, 2006
|
 |
